×
NeuroBo Pharmaceuticals EBITDA 2015-2024 | NRBO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
NeuroBo Pharmaceuticals ebitda from 2015 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
NeuroBo Pharmaceuticals EBITDA 2015-2024 | NRBO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
NeuroBo Pharmaceuticals ebitda from 2015 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$174.8B
Vertex Pharmaceuticals (VRTX)
$133.1B
Gilead Sciences (GILD)
$120.2B
Bristol Myers Squibb (BMY)
$109.8B
Regeneron Pharmaceuticals (REGN)
$91B
CSL (CSLLY)
$90.5B
GSK (GSK)
$75.2B
Alnylam Pharmaceuticals (ALNY)
$35.8B
Argenex SE (ARGX)
$35.6B
BioNTech SE (BNTX)
$26.3B
Biogen (BIIB)
$25.2B
Illumina (ILMN)
$24B
BeiGene (BGNE)
$20B
Moderna (MRNA)
$18B
Incyte (INCY)
$16.1B
Genmab (GMAB)
$15.3B
Vaxcyte (PCVX)
$13.3B
Insmed (INSM)
$13.2B
BioMarin Pharmaceutical (BMRN)
$12.8B
Bio-Techne Corp (TECH)
$12.1B
Sarepta Therapeutics (SRPT)
$11.6B
Exelixis (EXEL)
$10.4B
Revolution Medicines (RVMD)
$10.2B
QIAGEN (QGEN)
$10B
Intra-Cellular Therapies (ITCI)
$9.7B
Exact Sciences (EXAS)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$8.8B
Repligen (RGEN)
$7.9B
Halozyme Therapeutics (HALO)
$7.8B